Tumor Response and Secondary Resectability of Colorectal Liver Metastases Following Cetuximab with Chemotherapy: A Randomized, Controlled Study

Ye, L.; Zhu, Dan; Ren, Lili; Yin, Wei; Pan, Xia; Zhong, Yi; Liang, Leilei; Xu, Boyu; Liu, T.; Xu, Jiayue; Ren, Li; Ye, Wei; Wu, Hai-Liang; Ye, Q.; Fan, Jiaqi; Liu, Tianshu; Qin, Xuejun; Piessevaux, Hubert; Cutsem, Éric Van; Bokemeyer, Carsten; Schlichting, Michael; Heeger, Steffen; Tejpar, Sabine; Kim, Y. H.

doi:10.1093/annonc/mds556

Annals of Oncology

2012

DOI: 10.1093/annonc/mds556

|View full text |Cite

Tumor Response and Secondary Resectability of Colorectal Liver Metastases Following Cetuximab with Chemotherapy: A Randomized, Controlled Study

L. Ye¹,

Dan Zhu²,

Lili Ren³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC

Jin¹,

Amonkar

Aguiar-Ibáñez

et al. 2022

Future Oncol.

View full text Add to dashboard Cite

Aim: To compare pembrolizumab with competing interventions for previously untreated, unresectable or metastatic microsatellite instability-high or mismatch repair-deficient colorectal cancer. Method: Trials were identified via a systematic literature review and synthesized using a Bayesian network meta-analysis with time-varying hazard ratios (HRs). Results: Using intention-to-treat data, HRs for overall survival were generally in favor of pembrolizumab but not statistically significant; however, statistical significance was reached versus all comparators by month 16 when accounting for crossover. Estimated HRs for progression-free survival significantly favored pembrolizumab versus all comparators by month 12. Pembrolizumab was also superior to all comparators in terms of grade ≥3 adverse events. Conclusion: These analyses suggest that pembrolizumab is a highly efficacious and safe treatment in this population.

show abstract

Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC

Jin¹,

Amonkar

Aguiar-Ibáñez

et al. 2022

Future Oncol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tumor Response and Secondary Resectability of Colorectal Liver Metastases Following Cetuximab with Chemotherapy: A Randomized, Controlled Study

Cited by 1 publication

References 0 publications

Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC

Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC

Contact Info

Product

Resources

About